Primary visceral myopathy caused by a pathogenic mutation in the gene encoding the enteric smooth muscle actin gamma 2 (ACTG2) affects gastrointestinal and genitourinary tracts and often presents as chronic intestinal pseudoobstruction. We present a case of pediatric onset chronic intestinal pseudoobstruction associated with a novel missense ACTG2 mutation c.439G>T/p.G147C. In addition to the known disease manifestations of feeding intolerance and intestinal malrotation, our patient had a late-onset hypertrophic pyloric stenosis and a late-onset choledochal cyst, the former of which has not previously been described in patients with ACTG2-associated visceral myopathy.
Introduction
Chronic intestinal pseudoobstruction (CIPO) is an etiologically, pathologically, and clinically heterogeneous syndrome defined by ineffective intestinal peristalsis in the absence of a mechanical obstruction. CIPO is a manifestation of gastrointestinal neuromuscular pathology that may result from a primary developmental or genetic disorder or from secondary involvement by a systemic disorder such as diabetes, amyloidosis, or collagen vascular disease. [1] [2] [3] The primary gastrointestinal neuromuscular disorders are more likely to present in childhood; therefore, the term pediatric intestinal pseudoobstruction has recently been proposed to distinguish the pediatric onset disorders from adult onset CIPO. 4 Pathogenic mutations in the gene encoding the enteric smooth muscle contractile protein actin gamma 2 (ACTG2) are associated with a primary visceral myopathy that often presents with pediatric onset CIPO. 5 In this article, we describe a patient with pediatric onset CIPO associated with a novel missense germline ACTG2 mutation and unusual disease manifestations of hypertrophic pyloric stenosis and choledochal cyst.
Case Report
A male patient presented to our hospital at the age of 12 years for a second opinion and management of his symptoms of chronic intestinal obstruction. Prior to this, he had been managed for feeding intolerance since early infancy at an outside institution. He had undergone laparotomies for correction of intestinal malrotation and lysis of intestinal adhesions. More recently, he had developed persistent vomiting and poor gastric emptying secondary to pyloric obstruction, for which he had received pyloric dilations, botulinum toxin injections, total parenteral nutrition, and a gastrostomy. At our hospital, an abdominal radiograph showed a massively dilated stomach ( Figure 1A) . A 1 University of Texas Southwestern Medical Center, Dallas, TX, USA 2 Children's Health, Dallas, TX, USA laparotomy was performed and an 8 cm × 5 cm pyloric mass ( Figure 1B ) was found obstructing the gastric outlet. Additionally, there were dilated small bowel loops without an obstructing lesion. The pyloric mass was resected, and a primary gastroduodenostomy was performed. The patient improved clinically and his gastrostomy was taken down. Three years later, he presented with abdominal pain and distension with oral intake and resultant failure to thrive. Magnetic resonance cholangiopancreatography showed the common bile duct to be dilated to 2.3 cm in diameter with extension of ductal dilation into the intrahepatic ducts (Figure 2 ). Subsequent imaging demonstrated persistently dilated small bowel loops. He underwent a choledochal cyst resection, along with a cholecystectomy and a full-thickness biopsy of the duodenum. Due to persistent failure to thrive, he was started on total parenteral nutrition. He has also been on a regimen of cyclical antibiotics for treatment of small intestinal bacterial overgrowth that may cause mucosal inflammation, further impairing gastrointestinal motility. 6 Recently, he has been started on a trial of the enterokinetic pyridostigmine with mild relief of bloating. 7 
Pathologic Findings
Gross pathologic examination of the pyloric mass showed a diffuse thickening of the pyloric wall ( Figure 1C ). Histopathologic examination showed hyperplastic smooth muscle of the muscularis propria ( Figure 1D ), and the possibility of late-onset idiopathic hypertrophic pyloric stenosis was considered. In retrospect, occasional eosinophilic inclusions ( Figure 1D ), better demonstrated by immunohistochemical staining for smooth muscle actin ( Figure 1E ), were present in the cytoplasm of the smooth muscle cells. The full-thickness duodenal biopsy showed unremarkable mucosa and submucosa, normal-appearing myenteric and submucosal neural plexuses, and normal-appearing distribution of interstitial cells of Cajal as demonstrated by a CD117 immunostain. While the muscularis mucosae appeared unremarkable, the smooth muscle cells in the muscularis propria appeared disarrayed. Hematoxylin and eosin-stained sections suggested eosinophilic inclusions in the cytoplasm of the smooth muscle cells of the muscularis propria ( Figure 3A ). These ovoid to irregular inclusions did not stain with periodic acid Schiff stain ( Figure 3B ), but stained purple with Masson trichrome stain ( Figure 3C ) and pale blue with toluidine blue stain ( Figure 3D ). Immunostains for smooth muscle actin ( Figure 3E ) and muscle-specific actin highlighted the inclusions. By transmission electron microscopy, the inclusions corresponded to irregular aggregates of 9-to 11-nm filaments ( Figure  3F ). Immunostain for smooth muscle actin showed similar inclusions in the smooth muscle cells in the walls of the gallbladder and the choledochal cyst.
Molecular Findings
Deoxyribonucleic acid (DNA) was extracted from formalin-fixed and paraffin-embedded (FFPE) tissue (QIAamp DNA FFPE Tissue Kit, Qiagen, Hilden, Germany). The entire coding region of the ACTG2 gene was amplified using previously published primers. 8 Sanger sequencing identified a heterozygous missense mutation c.439G>T that results in replacement of the glycine at position 147 with cysteine (p.G147C, Figure 4A and B). The mutation was also confirmed in the DNA extracted from the patient's peripheral blood. This mutation has previously not been described (Table 1 ). 
Discussion
Mutations in the ACTG2 gene cause an autosomal dominant familial visceral myopathy that involves the intestines, the urinary bladder, and/or the uterus. 5, 9 The severity of the disease is variable. At the severe end of the spectrum, the disease may present at birth with megacystic microcolon intestinal hypoperistalsis syndrome (MMIHS), microcolon, megacystis and megaureter, and prune-belly syndrome. Other clinical presentations include recurrent urinary tract infections, bladder dysfunction, intestinal malrotation, feeding intolerance, cholecystitis/cholelithiasis, and CIPO. 5 While ACTG2-associated visceral myopathy causes intestinal pseudoobstruction, mechanical intestinal obstruction may also occur due to adhesions secondary to abdominal surgeries. However, mechanical obstruction due to hypertrophic pyloric stenosis as seen in our patient has not previously been described in ACTG2-associated visceral myopathy. We posit that hypertrophic pyloric stenosis seen in our patient is not an incidental finding but a feature of ACTG2-associated visceral myopathy because of the presence of smooth muscle actin-positive inclusions in the cytoplasm of the smooth muscle cells of the hypertrophied pyloric muscularis propria. Additional support for this association comes from the reports of hypertrophic pyloric stenosis in association with CIPO, intestinal malrotation, and short bowel in patients with X-linked periventricular nodular heterotopia caused by mutations in the gene encoding Filamin A (FLNA), which is an actin-binding protein that regulates actin cytoskeleton. [10] [11] [12] The absence of hypertrophic pyloric stenosis in the previously reported cases of ACTG2-associated visceral myopathy suggests that the previously undescribed ACTG2 mutation, c.439G>T/p. G147C, seen in our patient may be specifically associated with hypertrophic pyloric stenosis and/or there may be other unidentified genetic or epigenetic modifiers of the phenotype. Another unusual manifestation in our case was the acquired choledochal cyst first noted when the patient was 12 years old. Pertinently, smooth muscle positive inclusions were present in the cytoplasm of the smooth muscle cells of the choledochal cyst. Previously, Lu et al reported choledochal cyst in one infant with ACTG2-associated MMIHS. 13 The diagnosis of ACTG2-associated visceral myopathy is established in a patient by the presence of a heterozygous mutation in ACTG2. 5 The ACTG2 mutation, c.439G>T/p.G147C, seen in our patient has not previously been described. Including this mutation, there are now 23 known pathogenic variants of ACTG2-associated visceral myopathy (Table 1) . 8, 9, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] Twenty-two of these are missense mutations with one being a heterozygous tandem base substitution c.806_807delinsAA (p.G269E) reported in 7 affected members of a Swedish family. 9 In addition to these 23 mutations in patients with visceral myopathy, Wangler et al 22 identified an incidental nonsense variant (c.C187T, p.R63X) in ACTG2 by exome sequencing a group of approximately 1900 individuals. The individual with this ACTG2 variant reported intermittent mild constipation that did not require medications and had no history of abdominal surgery or bladder dysfunction. The authors concluded that ACTG2 haploinsufficiency is not clinically significant but cautioned that a mild phenotype with incomplete penetrance could not be excluded. 22 In in vitro studies, the pathogenic variants of ACTG2 show impaired polymerization and reduced incorporation into actin filaments, and their presence leads to reduced cell contractility. 8, 15, 18 In sarcoma cells, exogenous ACTG2-R148S interfered with endogenous actin cytoskeletal organization and cell contractility, suggesting a dominant negative effect of the mutant protein. 18 The novel mutation, p.G147C, seen in our patient affects the glycine that lies in a cleft that forms the binding site for the Wiskott-Aldrich syndrome homology region 2 (WH2)-containing proteins and other actin regulatory factors ( Figure 5A ), and that is also important for actin:actin contacts in the filament. 25, 26 This would explain the ultrastructural finding of disorganized actin filament aggregates and the light microscopic finding of actin-positive inclusions in the smooth muscle cells. Furthermore, the ACTG2 protein sequence, including the G147 residue, is evolutionarily highly conserved ( Figure 5B ). The mutation, c.439G>T/p.G147C, is predicted to be probably damaging by the computation tool PolyPhen-2 27 (score 0.998), damaging by the computation tool SIFT 28 (score 0.01), and deleterious by the computation tool PROVEAN 29 (score = −7.12). The reported histopathologic and immunohistochemical findings in ACTG2-associated visceral myopathy have been variable. Lehtonen et al reported ACTG2-positive intracellular inclusions as well as reduced ACTG2 staining in smooth muscle cells throughout the enteric muscularis propria in 4 affected members of a Finnish family. 18 Matera et al reported severe atrophy of muscularis propria, reduced connective fiber network, and large ganglia in one 7-yearold patient with ACTG2-associated CIPO. 19 In 4 patients with ACTG2-associated MMIHS, Lu et al reported loose and disordered arrangement of intestinal smooth muscle cells of the muscularis propria by light microscopy and vacuolar degeneration in the smooth muscle cells by transmission electron microscopy. 13 In a neonate with ACTG2-associated MMIHS, Korgali et al reported atrophic smooth muscle cells with attenuated muscularis propria in the small intestine; however, immunoreactivity for smooth muscle actin was preserved in the smooth muscle cells. Masson trichrome stain showed mural fibrosis and an immunostain for CD117 showed fewer interstitial cells of Cajal compared with an age-matched control. 17 In a 55-year-old female with ACTG2-associated CIPO, Holla et al reported haphazardly arranged and swollen smooth muscle cells with decreased immunohistochemical expression of smooth muscle actin in the muscularis propria and lack of separation between the inner circular and the outer longitudinal layers. There was also disordered myenteric neural plexus highlighted by S100 immunostain. The intestinal pathology specimen of that patient's deceased brother, initially suspected to have Crohn's disease, showed similar findings. 16 In one patient with a heterozygous tandem base substitution c.806_807delinsAA (p.G269E) in ACTG2, Klar et al reported normal light microscopic appearance of a full-thickness biopsy from the distal ileum and cecum with normal immunohistochemical staining for smooth muscle actin. 9 Histologic examination in our patient showed haphazardly arranged smooth muscle cells with smooth muscle actin-positive inclusions in the muscularis propria of the duodenum. Similar inclusions were also seen in the smooth muscle cells of the hypertrophic pyloric stenosis and in the walls of the gallbladder and the choledochal cyst. It is not yet clear if the variability in the reported histopathologic and immunohistochemical findings in ACTG2-associated visceral myopathy have a correlation with the underlying mutations or if there are additional genetic or epigenetic factors at play. In summary, we have described a novel missense ACTG2 mutation in a patient with CIPO and unusual disease manifestations of late-onset hypertrophic pyloric stenosis and choledochal cyst, thereby expanding the genetic, clinical, and pathologic phenotype of this uncommon disorder. 
